Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Mylan NV (MYL) Ordinary Shares EUR0.01

Sell:$21.50 Buy:$22.38 Change: $0.55 (2.47%)
NASDAQ:0.22%
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Sell:$21.50
Buy:$22.38
Change: $0.55 (2.47%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Sell:$21.50
Buy:$22.38
Change: $0.55 (2.47%)
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

Contact details

Address:
Unit 4, Trident Place, Mosquito Way
HATFIELD
AL10 9UL
United Kingdom
Telephone:
+44 (1707) 853000
Website:
https://www.mylan.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MYL
ISIN:
NL0011031208
Market cap:
$11.62 billion
Shares in issue:
515.87 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Rajiv Malik
    President, Executive Director
  • Heather Bresch
    Chief Executive Officer, Executive Director
  • Kenneth Parks
    Chief Financial Officer
  • Anthony Mauro
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.